T cell vaccination in systemic lupus erythematosus with autologous activated T cells
T cell vaccination in systemic lupus erythematosus with autologous activated T cells
复制标题
DOI：
10.1191/0961203305lu2239oa
复制
发表时间：
2005-01-01
期刊：
影响因子：
2.6
通讯作者：
Gao, XM
中科院分区：
文献类型：
--
作者：
Li, ZG;Mu, R;Gao, XM
系统性红斑狼疮（SLE）是一种自身反应性T细胞介导的自身免疫性疾病。用灭活的自身反应性T细胞免疫可诱导独特型抗独特型反应，以消耗参与SLE的自身反应性T细胞的特定亚群。对6例不适合或拒绝使用免疫抑制剂的SLE患者进行了T细胞疫苗接种治疗。评估其临床表现和实验室参数，包括混合淋巴细胞反应。自体反应性T细胞克隆来源于患者的外周血单核细胞，并分别在0、2、6和8周皮下接种1 × 10（7）个照射过的T细胞。随访时间32-40个月，间隔3 ~ 6个月。大多数患者接种后临床特征和实验室异常改善，而无需增加皮质类固醇和免疫抑制剂的剂量。SLE疾病活动指数（SLEDAI）评分降低。在6名患者中的4名中观察到对T细胞疫苗的免疫应答。在本报告时，6例患者仍处于临床缓解状态。在随访期间，未观察到疫苗接种的显著副作用。这项初步研究的结果表明，T细胞疫苗接种是一种安全有效的治疗系统性红斑狼疮。
Systemic lupus erythematosus (SLE) is an autoreactive T cell mediated autoimmune disease. Immunization with inactivated autoreactive T cells may induce idiotype anti-idiotypic reaction to deplete specific subsets of autoreactive T cells involved in SLE. Six SLE patients unsuitable or refused to use immunosuppressants were treated with T cell vaccination. Their clinical manifestations and laboratory parameters including mixed lymphocyte reactions were evaluated. Autoreactive T cell clones were derived from peripheral blood mononuclear cells of the patients and 1 X 10(7) irradiated T cells were inoculated subcutaneously at 0, two, six and eight weeks, respectively. The enrolled patients were followed up for 32-40 months at an interval of three to six months. The clinical characteristics and laboratory abnormalities improved after inoculation without increasing the dose of corticosteroids and immunosuppressants in most patients. SLE disease activity index (SLEDAI) scores decreased. Proliferative responses against the T cell vaccine were observed in four of six patients. At the time of this report, the six patients remain in clinical remission. No significant side effect from the vaccination was noticed during the follow-up period. The results of this pilot study indicate that T cell vaccination is a safe and effective treatment in SLE.